Technical Analysis for VIR - Vir Biotechnology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.65 | -1.41% | -0.10 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -1.41% | |
| NR7 | Range Contraction | -1.41% | |
| New 52 Week Low | Weakness | -1.41% | |
| Wide Bands | Range Expansion | -1.41% | |
| Down 3 Days in a Row | Weakness | -1.41% | |
| Down 4 Days in a Row | Weakness | -1.41% | |
| Down 5 Days in a Row | Weakness | -1.41% | |
| Oversold Stochastic | Weakness | -1.41% | |
| MACD Bearish Centerline Cross | Bearish | -4.11% | |
| New 52 Week Closing Low | Bearish | -4.11% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| New 52 Week Low | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 24 hours ago |
Get a Trading Sidekick!
- Earnings date: 10/31/2024
Vir Biotechnology, Inc. Description
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Immunology Infectious Diseases Coronavirus Influenza Therapeutic Products Hepatitis B Immunodeficiency Hepatitis B Virus Tuberculosis Alnylam Pharmaceuticals Treatment Of Hepatitis Dimm Treatment Of Hepatitis B Serious Infectious Diseases Therapeutic
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.09 |
| 52 Week Low | 6.62 |
| Average Volume | 1,098,453 |
| 200-Day Moving Average | 9.17 |
| 50-Day Moving Average | 7.94 |
| 20-Day Moving Average | 8.43 |
| 10-Day Moving Average | 8.48 |
| Average True Range | 0.54 |
| RSI (14) | 33.33 |
| ADX | 29.34 |
| +DI | 22.15 |
| -DI | 36.78 |
| Chandelier Exit (Long, 3 ATRs) | 8.81 |
| Chandelier Exit (Short, 3 ATRs) | 8.25 |
| Upper Bollinger Bands | 10.63 |
| Lower Bollinger Band | 6.22 |
| Percent B (%b) | 0.12 |
| BandWidth | 52.36 |
| MACD Line | -0.13 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.3148 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.35 | ||||
| Resistance 3 (R3) | 7.38 | 7.20 | 7.25 | ||
| Resistance 2 (R2) | 7.20 | 7.05 | 7.19 | 7.21 | |
| Resistance 1 (R1) | 6.97 | 6.95 | 6.88 | 6.94 | 7.18 |
| Pivot Point | 6.80 | 6.80 | 6.75 | 6.78 | 6.80 |
| Support 1 (S1) | 6.57 | 6.64 | 6.48 | 6.54 | 6.30 |
| Support 2 (S2) | 6.39 | 6.54 | 6.38 | 6.27 | |
| Support 3 (S3) | 6.16 | 6.39 | 6.23 | ||
| Support 4 (S4) | 6.13 |
